PATENT

RECEIVE

UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION OF Moriarty, R.M.; Penmasta, R.; Guo, L.; Rao, M.S.; and Mehta, R.G.

**TECH CENTER 1600/2900** Group No. 1616

SERIAL NO.: 09/008,957

Jan. 20, 1998

FILED:

 $1\alpha$ -HYDROXYVITAMIN D<sub>5</sub>,

ITS SYNTHESIS AND USE IN CANCER PREVENTION

AND THERAPY

Examiner: Badio

Box AF - FEE

TITLE:

Assistant Commissioner for Patents Washington, D.C. 20231

## AMENDMENT TRANSMITTAL LETTER

Dear Assistant Commissioner:

Transmitted herewith is an amendment in the above-identified application, along with the amendment fee calculated below:

	Claims Remaining After <u>Amendment</u>	Highest No. Previously <u>Paid For</u>	Additional <u>Fee</u>
Total No.	19	20	-0-
Independent	6	3	<u>-117-</u>
			\$117

The U.S. Patent Office is hereby authorized to charge any deficiency or credit any overpayment in the total fees indicated above to Deposit Account No. 50-0358. Telephone calls concerning the accompanying amendment should be directed to Harold J. Fassnacht, telephone number 312-201-0777.

Respectfully submitted,

12/14/1999 DVUONG 00000075 09008957

01 FC:202

117.00 OP

Harold J/ Kassnacht Req. No.  $\sqrt{35,507}$ 

BULLWINKEL PARTNERS, LTD. 19 S. LaSalle Street - Suite 1300 Chicago, Illinois 60603-1493 Telephone: 312-201-0777

Dated: December 10, 1999

DE 13 1999 E

E UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION OF Moriarty, R.M.; Penmasta, R.; Guo, L.; Rao, M.S.; and Mehta, R.G.

Jan. 20, 1998

Group No. 1616

TECH CENTER 1600/29

SERIAL NO.: 09/008,957

) Examiner: Badio

TITLE:

FILED:

 $1\alpha$ -HYDROXYVITAMIN D<sub>5</sub>, ITS SYNTHESIS AND USE IN CANCER PREVENTION AND THERAPY

Box AF - FEE
Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED

DEC 14 1999

TC 1700 MAIL ROO

## SUBMISSION UNDER 37 CFR § 1.116 (AMENDMENT AFTER FINAL OFFICE ACTION)

Sir:

In response to the Final Office Action of September 10, 1999

Applicants offer the following amendments and comments, and respectfully request reconsideration of this application.

Please amend the above-identified application as follows:

## In the claims:

2. (Twice Amended) A compound of the formula [I of claim 1 wherein]:

